PT1663183E - FORMA FARMACjUTICA SÓLIDA - Google Patents

FORMA FARMACjUTICA SÓLIDA Download PDF

Info

Publication number
PT1663183E
PT1663183E PT04816820T PT04816820T PT1663183E PT 1663183 E PT1663183 E PT 1663183E PT 04816820 T PT04816820 T PT 04816820T PT 04816820 T PT04816820 T PT 04816820T PT 1663183 E PT1663183 E PT 1663183E
Authority
PT
Portugal
Prior art keywords
dosage form
pharmaceutical dosage
solid pharmaceutical
ritonavir
pharmaceutically acceptable
Prior art date
Application number
PT04816820T
Other languages
English (en)
Inventor
Joerg Rosenberg
Joerg Breitenbach
Ulrich Reinhold
Bernd Liepold
Gunther Derndl
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1663183(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PT1663183E publication Critical patent/PT1663183E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT04816820T 2003-08-28 2004-08-23 FORMA FARMACjUTICA SÓLIDA PT1663183E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/650,178 US20050048112A1 (en) 2003-08-28 2003-08-28 Solid pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
PT1663183E true PT1663183E (pt) 2011-08-25

Family

ID=34217089

Family Applications (5)

Application Number Title Priority Date Filing Date
PT101812501T PT2258344E (pt) 2003-08-28 2004-08-23 Forma farmacêutica sólida que compreende uma dispersão sólida de ritonavir e lopinavir
PT151693785T PT2942051T (pt) 2003-08-28 2004-08-23 Forma de dosagem farmacêutica sólida compreendendo uma dispersão sólida de inibidor de protease de vih
PT101812683T PT2258346T (pt) 2003-08-28 2004-08-23 Forma farmacêutica sólida que compreende uma dispersão sólida de inibidor da protease do vih
PT101812642T PT2258345T (pt) 2003-08-28 2004-08-23 Forma farmacêutica sólida que compreende uma dispersão sólida de inibidor da protease do vih
PT04816820T PT1663183E (pt) 2003-08-28 2004-08-23 FORMA FARMACjUTICA SÓLIDA

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PT101812501T PT2258344E (pt) 2003-08-28 2004-08-23 Forma farmacêutica sólida que compreende uma dispersão sólida de ritonavir e lopinavir
PT151693785T PT2942051T (pt) 2003-08-28 2004-08-23 Forma de dosagem farmacêutica sólida compreendendo uma dispersão sólida de inibidor de protease de vih
PT101812683T PT2258346T (pt) 2003-08-28 2004-08-23 Forma farmacêutica sólida que compreende uma dispersão sólida de inibidor da protease do vih
PT101812642T PT2258345T (pt) 2003-08-28 2004-08-23 Forma farmacêutica sólida que compreende uma dispersão sólida de inibidor da protease do vih

Country Status (31)

Country Link
US (1) US20050048112A1 (pt)
EP (6) EP3354261A1 (pt)
JP (6) JP4815348B2 (pt)
KR (5) KR101457967B1 (pt)
CN (5) CN102764244A (pt)
AT (1) ATE516017T1 (pt)
AU (3) AU2004283087C1 (pt)
CA (2) CA2689639C (pt)
CR (3) CR8256A (pt)
CY (5) CY1111981T1 (pt)
DK (5) DK2258346T3 (pt)
EA (4) EA011924B1 (pt)
EC (1) ECSP066397A (pt)
ES (5) ES2608720T3 (pt)
HK (1) HK1257502A1 (pt)
HR (1) HRP20110555T1 (pt)
HU (3) HUE038792T2 (pt)
IL (3) IL173939A (pt)
ME (2) MEP17608A (pt)
MX (2) MX358033B (pt)
NO (3) NO330282B1 (pt)
NZ (2) NZ545499A (pt)
PL (5) PL2258345T3 (pt)
PT (5) PT2258344E (pt)
RS (2) RS57663B1 (pt)
SG (3) SG145690A1 (pt)
SI (5) SI2258345T1 (pt)
TW (1) TWI342221B (pt)
UA (1) UA85564C2 (pt)
WO (1) WO2005039551A2 (pt)
ZA (3) ZA200801362B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
EP1962808B1 (en) * 2005-12-14 2010-09-29 F. Hoffmann-La Roche AG Hcv prodrug formulation
ATE474560T1 (de) * 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
UY30535A1 (es) * 2006-08-10 2008-03-31 Cipla Ltd Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
JP5750266B2 (ja) * 2008-02-28 2015-07-15 アッヴィ・インコーポレイテッド 錠剤およびその調製
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
US20110034489A1 (en) 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2829186A1 (en) * 2011-03-07 2012-09-13 Bandi Parthasaradhi Reddy Amorphous form of lopinavir and ritonavir mixture
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2714683A4 (en) 2011-05-27 2014-11-05 Hetero Research Foundation RITONAVIR AMORPH CO-PRECIPITATION
CN103732216A (zh) * 2011-08-16 2014-04-16 默沙东公司 无机基质和有机聚合物组合用于制备稳定的无定形分散体的用途
EP2564832A1 (en) 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
US9370578B2 (en) 2012-03-07 2016-06-21 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
CA2866203A1 (en) * 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
WO2014048783A1 (en) 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
WO2014048782A1 (en) 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190038754A1 (en) * 2017-08-07 2019-02-07 SE Tylose, USA, Inc. Pharmaceutical composition in solid extruded form
US20210361639A1 (en) * 2018-03-02 2021-11-25 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN113318076B (zh) * 2021-06-02 2022-09-23 聊城大学 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法
CN114557967B (zh) * 2022-03-17 2023-06-02 乐普制药科技有限公司 一种利托那韦固体分散体的制备方法
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5542206A (en) 1994-10-11 1996-08-06 Lisch; Albert Lure and tackle stacking container
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19841244A1 (de) * 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
PT1183026E (pt) 1999-06-04 2006-11-30 Abbott Lab Formulações farmacêuticas melhoradas incluindo ritonavir
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
WO2001034118A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Solid dispersion pharmaceutical formulations
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
DE10213242A1 (de) 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations

Also Published As

Publication number Publication date
NZ545499A (en) 2009-11-27
ME00130B (me) 2010-10-10
JP5903413B2 (ja) 2016-04-13
PT2942051T (pt) 2018-04-23
ATE516017T1 (de) 2011-07-15
ZA200601718B (en) 2009-11-25
AU2010238573A1 (en) 2010-11-18
ZA200801361B (en) 2011-11-30
MEP17608A (en) 2010-06-10
CN102772380B (zh) 2015-08-19
PL2258345T3 (pl) 2017-03-31
RS57663B1 (sr) 2018-11-30
EA201890737A3 (ru) 2019-01-31
MX358033B (es) 2018-08-02
MXPA06002346A (es) 2006-05-19
NO20131743L (no) 2006-05-29
RS20181262A1 (sr) 2019-02-28
CR8256A (es) 2008-01-11
KR101132602B1 (ko) 2012-04-06
CY1118505T1 (el) 2017-07-12
CA2689639C (en) 2014-06-10
CN102764244A (zh) 2012-11-07
HK1145969A1 (en) 2011-05-13
TWI342221B (en) 2011-05-21
EP3354261A1 (en) 2018-08-01
EP1663183B9 (en) 2012-06-13
KR20140046078A (ko) 2014-04-17
ECSP066397A (es) 2006-08-30
HUE038792T2 (hu) 2018-11-28
JP2011126898A (ja) 2011-06-30
NO335326B1 (no) 2014-11-10
EP2258346B1 (en) 2017-09-27
EP2942051B1 (en) 2018-01-17
EA200900292A1 (ru) 2009-06-30
EP2258345B1 (en) 2016-09-21
DK2258345T3 (en) 2017-01-16
EP2258346A3 (en) 2011-01-19
JP2018035163A (ja) 2018-03-08
CR20120662A (es) 2013-03-13
JP5395125B2 (ja) 2014-01-22
CR20120661A (es) 2013-03-13
US20050048112A1 (en) 2005-03-03
EP2258345A3 (en) 2011-01-19
CY1119651T1 (el) 2018-04-04
EP2258346A2 (en) 2010-12-08
NZ579622A (en) 2011-01-28
WO2005039551A2 (en) 2005-05-06
PL2258344T3 (pl) 2013-04-30
EA033224B1 (ru) 2019-09-30
DK2258344T3 (da) 2013-01-02
CN1901884A (zh) 2007-01-24
EP2258345A2 (en) 2010-12-08
WO2005039551A3 (en) 2006-08-03
IL207260A (en) 2017-10-31
SI1663183T1 (sl) 2011-09-30
TW200522979A (en) 2005-07-16
AU2007249115B2 (en) 2010-08-12
JP2007504142A (ja) 2007-03-01
HK1094766A1 (en) 2007-04-13
CN102772380A (zh) 2012-11-14
EA020992B1 (ru) 2015-03-31
SI2942051T1 (en) 2018-06-29
ES2666390T3 (es) 2018-05-04
ES2399810T3 (es) 2013-04-03
AU2004283087A1 (en) 2005-05-06
KR20060121837A (ko) 2006-11-29
EA201890737A2 (ru) 2018-08-31
DK1663183T3 (da) 2011-08-29
CA2689639A1 (en) 2005-05-06
SI2258345T1 (sl) 2017-01-31
ES2367173T3 (es) 2011-10-31
SG145690A1 (en) 2008-09-29
AU2004283087C1 (en) 2008-04-24
AU2004283087B2 (en) 2007-09-20
ES2608720T3 (es) 2017-04-12
RS20060140A (sr) 2008-09-29
CY1111981T1 (el) 2015-11-04
DK2942051T3 (en) 2018-05-07
NO20061342L (no) 2006-05-29
PL1663183T3 (pl) 2011-10-31
NO20100367L (no) 2006-05-29
IL254581A0 (en) 2017-11-30
JP2013241460A (ja) 2013-12-05
EP1663183B1 (en) 2011-07-13
HK1257502A1 (en) 2019-10-25
CN1901884B (zh) 2012-07-25
DK2258346T3 (da) 2017-11-13
PL2258346T3 (pl) 2018-01-31
SG10201507902UA (en) 2015-10-29
NO330282B1 (no) 2011-03-21
KR101457967B1 (ko) 2014-11-07
ZA200801362B (en) 2009-03-25
HK1217298A1 (en) 2017-01-06
EP2942051A1 (en) 2015-11-11
JP2011236232A (ja) 2011-11-24
EP1663183A2 (en) 2006-06-07
CN105106104A (zh) 2015-12-02
KR20120054666A (ko) 2012-05-30
CN101919858A (zh) 2010-12-22
ES2653762T3 (es) 2018-02-08
SG179401A1 (en) 2012-04-27
SI2258344T1 (sl) 2013-03-29
NO334418B1 (no) 2014-03-03
HUE031153T2 (en) 2017-07-28
KR101563222B1 (ko) 2015-10-26
PT2258346T (pt) 2017-10-24
EP2258344A3 (en) 2011-01-19
SI2258346T1 (sl) 2017-12-29
AU2010238573B2 (en) 2012-12-13
EP2258344A2 (en) 2010-12-08
CA2536638C (en) 2010-04-06
RS59969B1 (sr) 2020-03-31
EA011924B1 (ru) 2009-06-30
JP2016094433A (ja) 2016-05-26
CA2536638A1 (en) 2005-05-06
IL173939A (en) 2017-03-30
PT2258345T (pt) 2017-01-20
IL173939A0 (en) 2006-07-05
EA201301045A1 (ru) 2014-05-30
KR20150044031A (ko) 2015-04-23
JP4815348B2 (ja) 2011-11-16
EA200600473A1 (ru) 2006-10-27
KR101281994B1 (ko) 2013-07-04
HUE035985T2 (hu) 2018-06-28
CY1113596T1 (el) 2016-06-22
KR20110122771A (ko) 2011-11-10
PL2942051T3 (pl) 2018-07-31
AU2007249115A1 (en) 2008-01-10
EP2258344B1 (en) 2012-11-14
UA85564C2 (ru) 2009-02-10
PT2258344E (pt) 2013-02-18
CN101919858B (zh) 2013-10-30
HRP20110555T1 (hr) 2011-09-30
CY1120138T1 (el) 2018-12-12
JP5498411B2 (ja) 2014-05-21

Similar Documents

Publication Publication Date Title
IL254581A0 (en) Solid pharmaceutical dosage form
WO2004032866A3 (en) Therapeutic formulations
WO2006039499A3 (en) Method for improving the biovailability of orally delivered therapeutics